SCHEMBL17661839

SCHEMBL17661839

CSc1nc(N)cc(Oc2ccc(-c3cnc(Cc4cccc(C(F)(F)F)c4)[nH]3)cc2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.55
KIT P10721 1/20 0.55
PDGFRA P16234 1/20 0.55
CDK11B P21127 1/20 0.55
FLT3 P36888 1/20 0.55
CDKL2 Q92772 1/20 0.55
HPGDS O60760 1/20 0.38
MPO P05164 1/20 0.37
SCN10A Q9Y5Y9 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SCN2A Q99250 2/20 0.36
LTA4H P09960 1/20 0.36
BRAF P15056 1/20 0.36
KDR P35968 1/20 0.36
MAPK14 Q16539 1/20 0.36
TNNI3K Q59H18 1/20 0.36
MAOB P27338 2/20 0.36
SLC2A1 P11166 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17658742 0.89 PDGFRB (0.42) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL625061 0.82 PDGFRB (0.67) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL17662102 0.73 PDGFRB (0.45) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL625598 0.72 PDGFRB (0.73) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949225 0.72 PDGFRB (0.51) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL12336564 0.71 PDGFRB (0.66) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL17661802 0.71 MET (0.42) PDGFRBHPGDSBRAFKDRMAPK14
SCHEMBL29352982 0.71 PDGFRB (1.00) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL12336691 0.70 PDGFRB (0.62) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL626404 0.69 PDGFRB (0.65) PDGFRBKITPDGFRACDK11BFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.